Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Scheel

Showing results (161-170 of 169) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 169 results.
Blood|April 7, 2016
B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in miceGero Knittel, Paul Liedgens, Darya Korovkina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR InhibitorsSandra Ortiz-Cuaran, Matthias Scheffler, Dennis Plenker, et al.
The Journal of Clinical Investigation|August 22, 2023
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancerFlorian Malchers, Lucia Nogova, Martijn Ha van Attekum, et al.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical TrialSebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysMatthias Scheffler, Michaela A Ihle, Rebecca Hein, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
Nature Biomedical Engineering|December 10, 2024
Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinomaAristeidis Papargyriou, Mulham Najajreh, David P Cook, et al.
Nature|March 14, 2024
Evolutionary trajectories of small cell lung cancer under therapyJulie George, Lukas Maas, Nima Abedpour, et al.
Pageof 17

Showing results (161-170 of 169) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 169 results.
Blood|April 7, 2016
B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in miceGero Knittel, Paul Liedgens, Darya Korovkina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR InhibitorsSandra Ortiz-Cuaran, Matthias Scheffler, Dennis Plenker, et al.
The Journal of Clinical Investigation|August 22, 2023
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancerFlorian Malchers, Lucia Nogova, Martijn Ha van Attekum, et al.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical TrialSebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysMatthias Scheffler, Michaela A Ihle, Rebecca Hein, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
Nature Biomedical Engineering|December 10, 2024
Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinomaAristeidis Papargyriou, Mulham Najajreh, David P Cook, et al.
Nature|March 14, 2024
Evolutionary trajectories of small cell lung cancer under therapyJulie George, Lukas Maas, Nima Abedpour, et al.
Pageof 17